Ann: Imugene HER-Vaxx Presentation at AACR 2021 Meeting, page-5

Exert

The AACR presentation highlights and presents the following new data;
x Treatment with HER-Vaxx clearly demonstrates that all patients develop high levels of HER2-
specific antibodies early in the treatment protocol.
x Analysis of the antibody data reveals high levels are maintained during the treatment and
maintenance phases, with only minimal booster injections of HER-Vaxx required to maintain
the high levels.
x The constant and high HER2 antibody levels correlate with the early separation of the
Kaplan Meier (KM) Curves for overall survival (OS) and progression free survival (PFS)
clinical trial endpoints. The Kaplan Meier Curve provides a recognised statistical estimation
of the survival function which visually represents the probability of an event occurring for
each treatment arm at a respective time interval.
x Overall, this interim data is suggestive that the treatment is effective and well tolerated with
an overall survival benefit that is superior to chemotherapy alone.
Final tumour response, correlation of antibodies with tumour response, and final PFS and OS data
is expected to read out in 2021.
Imugene’s HER-Vaxx is a B-cell peptide cancer immunotherapy designed to treat tumours that overexpress the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. The
immunotherapy is constructed from several B cell epitopes derived from the extracellular domain
of HER-2/neu. It has been shown in pre-clinical studies and in Phase 1 and 2 studies to stimulate a
potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target.